Daiichi Sankyo just announced an up to $5.5 billion joint development agreement with Rahway, for three precision cancer drug candidates, in a deal that could generate up to $16 billion more -- depending on milestone achievements.
All three drug candidates belong to the class of drugs known as antibody drug conjugates (ADC) and are in various stages of clinical development for the treatment of an array of solid cancer tumors. Here's the latest, from Reuters:
. . .Under the deal, Merck will pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next two years. Merck may make additional payments of up to $16.5 billion contingent on future sales milestones.
Shares of Daiichi Sankyo surged in Tokyo trade and were up 12% at 0046 GMT. . . .
Now you know. And the graphic is largely speculation on my part, but this deal may solve some long running patent disputes -- which have now become part of Seagen's acquired tool box at Pfizer, now that it is no longer independent. We will watch for evidence of that late night, back-porch horse trading. Onward.
नमस्ते
No comments:
Post a Comment